Clinical trials
Lupus Erythematosus clinical trials
Below are recruiting lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07000916Recruiting
Follow-up study for new arthritis in kids and young adults
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
BrusselsAges 2–50 - NCT07005479Recruiting
Long-term lupus study at Peking University Hospital
This study looks at the long-term health of people with lupus. It aims to understand how the disease progresses over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT07049653Recruiting
Anifrolumab pregnancy safety study
This study looks at pregnancy outcomes in women with lupus (SLE) who were or were not treated with the drug anifrolumab. It helps understand if anifrolumab is safe to use during pregnancy.
Cary, North CarolinaAges 18–130 - NCT07056621Recruiting
How belimumab changes lupus over time
This study looks at how the drug belimumab affects the long-term course of lupus. It compares patients who receive belimumab to similar patients who do not, to see if it helps control disease activity over time.
Athens, AtticaAges 18 years+ - NCT07072611RecruitingEarly Phase 1
Safety study of SOF-SKN cream in healthy volunteers
This study tests a cream called SOF-SKN on healthy people to see if it's safe and how the body handles it. It is a first-in-human trial, so if you join, you'll help researchers learn about the cream before testing it in patients.
Melbourne, VictoriaAges 18–64 - NCT07077304Recruiting
Cardiac imaging study for inflammatory heart diseases
This study uses heart scans (MRI or nuclear imaging) to better understand inflammatory heart conditions. If you have a suspected inflammatory heart disease and are already scheduled for one of these scans, you may be able to join.
ParisAges 18 years+ - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07102030Recruiting
Understanding lupus subgroups to improve treatment
This study is trying to better understand lupus (SLE) by looking at different types of the disease. It may help doctors find more personalized treatments in the future.
StockholmAges 18–100 - NCT07148115Recruiting
Pregnancies before lupus diagnosis
This trial studies women who had at least one pregnancy before being diagnosed with lupus. It aims to understand how lupus may have affected those pregnancies.
Aïn Taya, Algiers ProvinceAges 18–55 - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07177911RecruitingPhase 1
Study of CC312 for moderate to severe lupus
This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
Chengdu, SichuanAges 18–65 - NCT07185269RecruitingPhase 1/Phase 2
Testing 626 for lupus: a phase 1/2 study
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
Beijing, Beijing MunicipalityAges 18–70 - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07219563RecruitingPhase 1
Alnuctamab for hard-to-treat lupus (LATTE Study)
This trial tests a new drug called alnuctamab for people with lupus (SLE) that hasn't responded to multiple standard treatments. It aims to see if targeting certain immune cells can reduce lupus activity.
New York, New YorkAges 18–60 - NCT07233642RecruitingPhase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT07274059RecruitingEarly Phase 1
CAR-T cell therapy from cord blood for lupus
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
Yancheng, JiangsuAges 18–75 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07318259RecruitingPhase 1
Study of a new CAR-T therapy for lupus
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
Nanjing, JiangsuAges 18 years+ - NCT07331467RecruitingPhase 1
Ultra-fast CAR-T cell therapy for lupus
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
Nanjing, JiangsuAges 18 years+ - NCT07339540RecruitingEarly Phase 1
BCMA gene therapy for recurring autoimmune diseases
This early-phase trial tests a new gene therapy (BCMA LV injection) for people with autoimmune diseases like lupus, IgG4-related disease, scleroderma, myositis, or vasculitis that keep coming back or don't respond to standard treatments. The goal is to see if targeting a specific immune cell protein (BCMA) can help control the disease.
Wuhan, HubeiAges 18–65
Hear when a new Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus?
- Yes. Clin2 currently lists 260 recruiting lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.